Medical Condition News

RSS

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Pfizer Inc. today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

20 Jul 2010

Combined technologies offer promise for detecting colon cancer in women

A team led by a Northwestern University biomedical engineer has found that combining novel optical technologies with a common colon cancer screening test may allow doctors to more accurately detect the presence of colon cancer, particularly in women.

20 Jul 2010

Vertos Medical announces 12-week data from MiDAS I clinical study for lumbar spinal stenosis

Medical device company Vertos Medical Inc. has announced the unveiling of 12-week clinical data from its prospective, 75-patient MiDAS I (mild Decompression Alternative to open Surgery) study that further validate the safety and efficacy of mild for the treatment of lumbar spinal stenosis (LSS). Consistent with the positive six-week study results released in March and May, the new MiDAS I data demonstrate that mild patients continued to experience statistically significant improvement in pain, physical function and mobility 12 weeks following treatment.

20 Jul 2010

Vitamin D supplements could help preteen girls set stage for a lifetime of strong bones: Study

"Eat your veggies," "Don't run with scissors" and now "Take your calcium and vitamin D." A clinical study conducted at the School of Exercise Science at Australian Catholic University has shown that taking high quality calcium supplements like USANA's Active Calcium could help preadolescent girls set the stage for a lifetime of strong, mineral-rich bones.

20 Jul 2010

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Bioengineers from Rice University's BioScience Research Collaborative have won a $1.7 million grant from the National Institutes of Health to develop an injectable mix of polymers and adult stem cells that can spur the growth of new cartilage in injured knees and other joints.

20 Jul 2010

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

RegeneRx Biopharmaceuticals, Inc. today announced a research team from the Henry Ford Hospital in Detroit, MI, reported that Thymosin beta 4, administered to rats after embolic stroke, improved neurological functional outcome compared to control animals.

20 Jul 2010

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.

20 Jul 2010

Plea for Federal legislation to ban mercury in vaccines, prevent autism

Two papers in this week's neuroscience journal Acta Neurobiologiae Experimentalis point to vaccines and heavy metals including mercury as causes of the alarming rise in autism. The Centers for Disease Control now estimate autism to affect one in 110 children, up 40% from just a few years ago.

20 Jul 2010

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Here are highlights from the July issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required.

20 Jul 2010

Researchers discover new gene regulation, DNA behavior of breast cancer cells

Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.

20 Jul 2010

John Theurer Cancer Center to acquire TrueBeam system for treating cancer patients

In a promising development for cancer patients in New Jersey and surrounding areas, the John Theurer Cancer Center at Hackensack University Medical Center announced today that it will be the first cancer center in New Jersey to acquire an innovative system that enables a radically different approach to treating cancer with image-guided radiotherapy known as the TrueBeam- system.

20 Jul 2010

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Kidney disease is a growing public health problem, with approximately half a million individuals in the United States requiring dialysis treatments to replace the function of their failed kidneys. The problem is particularly acute among African-Americans, whose rates of kidney disease are four times higher than those of European Americans.

20 Jul 2010

Researchers identify a mechanism that explains different phases of CML progression

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia.

20 Jul 2010

Benefits of drug L-methionine for neurogenic bladder disorders unclear

It is unclear whether patients with neurogenic bladder disorders benefit from the drug L-methionine. The only study currently available provides neither proof of benefit nor proof of harm. This is the result of a report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 12 July 2010.

20 Jul 2010

Researchers monitor stress during a real-time war to refine PTSD therapy

Psychologists aren't usually called to the battlefield, but the 2008-09 Gaza War gave Tel Aviv University researchers a unique picture of how anxiety manifests during stressful situations.

20 Jul 2010

DEKA Medical announces availability of new SmartXide DOT HP Fractional CO2 laser

DEKA Medical announced today the immediate availability of the High-Powered SmartXide DOT. The new SmartXide DOT HP Fractional CO2 laser, with average power of 50W, can attain irradiance of up to 250W of power with each pulse. This makes the new SmartXide DOT HP the most powerful superpulse CO2 laser available to aesthetic physicians.

19 Jul 2010

Amira achieves two clinical development milestones in FLAP program for asthma

"Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."

19 Jul 2010

IBA Dosimetry to showcase Blue Phantom[2] radiation therapy commissioning solution with LDA-99SC at AAPM

IBA Dosimetry, member of IBA Group, will showcase its latest innovation in radiation therapy commissioning solutions, the Blue Phantom[2] water phantom equipped with advanced Linear Diode Array technology (LDA-99SC), at the American Association of Physicists in Medicine Annual Meeting in Philadelphia, July 18 - 22, 2010.

19 Jul 2010

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.

19 Jul 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

19 Jul 2010

Medical Condition News

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Combined technologies offer promise for detecting colon cancer in women

Vertos Medical announces 12-week data from MiDAS I clinical study for lumbar spinal stenosis

Vitamin D supplements could help preteen girls set stage for a lifetime of strong bones: Study

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

Plea for Federal legislation to ban mercury in vaccines, prevent autism

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Researchers discover new gene regulation, DNA behavior of breast cancer cells

John Theurer Cancer Center to acquire TrueBeam system for treating cancer patients

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Researchers identify a mechanism that explains different phases of CML progression

Benefits of drug L-methionine for neurogenic bladder disorders unclear

Researchers monitor stress during a real-time war to refine PTSD therapy

DEKA Medical announces availability of new SmartXide DOT HP Fractional CO2 laser

Amira achieves two clinical development milestones in FLAP program for asthma

IBA Dosimetry to showcase Blue Phantom[2] radiation therapy commissioning solution with LDA-99SC at AAPM

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News